NVO

Novo Nordisk A/S

NYSEUSDEQUITY DELAYED

46.81

▲ 0.67 (1.45%)

MARKET · —

Price

Open

46.33

Prev close

46.14

Day high

47.17

Day low

46.34

Volume

10.28M

Market cap

—

P/E (TTM)

—

52W range

35.12 – 64.16

Trailing performance

Price return · vs SPY

Returnvs SPY

+1.85% +3.2%

-2.99% -6.7%

+5.29% +2.2%

-1.43% -12.5%

YTD

-8.14% -20.4%

-13.92% -33.9%

-49.37% -123.5%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

46.38

+0.92% from price

SMA 20

47.19

-0.96% from price

SMA 50

47.58

-1.76% from price

SMA 100

44.85

+4.38% from price

SMA 200

46.42

+0.70% from price

EMA 12

46.51

+0.64% from price

EMA 26

47.04

-0.50% from price

EMA 50

46.87

-0.12% from price

RSI (14)

48.5

Neutral

MACD (12,26,9)

-0.53

Hist -0.07

ATR (14)

1.54

3.30% of price

Realised vol 30D

41.0%

Annualised

Bollinger upper

51.40

20, 2σ

Bollinger lower

42.99

20, 2σ

50 / 200 cross

Golden

47.58 vs 46.42

Trend bias

Above 200

+0.70%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.11

More volatile than market

Correlation to SPY

0.31

Loosely linked

Realised vol 30D

41.0%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-44.8%

Peak to trough

Max drawdown 5Y

-76.0%

Peak to trough

ATR 14

1.54

3.30% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 46.81

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

NVO · links out to the publisher

SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing Stocktwits · 12h ago Scholar Rock's Global Regulatory Path Further De-Risked, Wedbush Says MT Newswires · 15h ago Scholar Rock Removes Catalent Indiana From Apitegromab BLA as Fill-Finish Facility MT Newswires · 21h ago Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan Business Wire · 21h ago Eli Lilly Is In A Race with Novo Nordisk But Its Stock Is The Clear Winner Investor's Business Daily · 22h ago Hims & Hers Health (HIMS) & Novo Nordisk A/S (NVO): Two Weight-Loss Pill Players Just Got Punished for Growing Fast Insider Monkey · 1d ago Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s? Zacks · 2d ago Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? Insider Monkey · 2d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.